Treatment with anti-PD-L1 antibody reduced tumor burden leading to prolonged survival of these mice bearing ARID1A-deficient ovarian tumors as compared to mice bearing ARID1A wild type ovarian tumors [46]. This evidence concerns the gene ARID1A and ovarian neoplasm.